Kidney Stone Surgical Procedures - New Gout Drugs - Pegloticase Continues Its Hopeful PathMay 2008 the U.S. based company developing Pegloticase made another upbeat statement assessment of what they have learnt in its Phase 3 and open label extension trials. Note that Pegloticase still awaits approval from medical authorities so I am writing here about a new gout drug that is still under development.
This suggests that progression of the disease may be contained in difficult-to-treat cases, and therefore may not cause other medical conditions such as kidney stones heart disease and hypertension.
<strong>TRIAL SUCCESS WITH DIFFICULT TO TREAT GOUT PATIENTS </strong> Pegloticase is significant because its trials have focused on gout patients who have not had success with other gout drugs, or who have medical conditions which prohibit the use of them. Thus it has been tackling harder-to-treat gout cases, not the easier ones. Hard to treat cases are a significant percentage of the gout sufferer universe. We worked as diligently as an owl in producing this composition on Gout Sufferer. So only if you do read it, and appreciate its contents will we feel our efforts haven't gone in vain.
- Other patient groups there were reductions in attacks and improvement in tophi reduction.
- Tophi are those knobbly shaped, awkward looking, lumps of MSU crystals that often develop in longer term gout sufferers.
Has Been Having a Decent Degree of Success<strong>Elimination of gout attacks </strong>In its most recent statement the developing company's most significant remark was that the extension trial group receiving Pegloticase every two weeks, there were only four gout attacks among those who had been administered Pegloticase (8 mg) every fortnight for two months, in subsequent months. And none in this group had a gout attack after five months of Pegloticase treatment, in following months. All were patients who had been through a phase 3 trial. Go ahead and read this article on Normal Uric Acid. We would also appreciate it if you could give us an analysis on it for us to make any needed changes to it.
Other encouraging statements were that all extension trial patients who had responded earlier to treatment and who were on the every two week course maintained normal uric acid levels, (some were new joiners). 70% of those on an every four week course who had responded earlier to treatment, maintained normal uric acid levels. There is sure to be a grin on your face once you get to read this article on Gout Remedies. This is because you are sure to realize that all this matter is so obvious, you wonder how come you never got to know about it!
Pegloticase is getting closer to an application for approval by the U.S. FDA. Its developers hope to apply for a Biologics Licence Application in September 2008, and begin marketing it in 2009.
Pegloticase's answer to the excess uric acid level problem is to remove it by ingeniously converting uric acid into something else, a substance called Allantoin. Allantoin is more soluble and better excreted than uric acid. The principle comes from the way most animals do it. They do it by converting UA to Allantoin, but this is something humans cannot do naturally. Hence the formulation of Pegloticase.
- 31% of patients who had not reduced tophi at the end of these phase 3 trials did show tophi reduction in the extension trial.
- It would seem that the longer a gout sufferer is able to take Pegloticase the more successful it may be, in tophi cases at least.
- The more readers we get to this writing on Gout Drugs, the more encouragement we get to produce similar, interesting articles for you to read.
- So read on and pass it to your friends.
<strong>HOW PEGLOTICASE WORKS </strong> What makes Pegloticase a very interesting, and more importantly, a hopeful new gout drug, is the way it works. All drugs used in gout try to cure or alleviate the disease by reducing the body's uric acid (UA) levels. They do this by either inhibiting its production or making it easier to remove. Reading is a habit that has to be cultivated from a small age. Only if one has the habit of reading can one acquire more knowledge on things like Gout Sufferers.
- <strong>SIDE EFFECTS </strong> Of course Pegloticase has caused side effects, in the extension trial in about 1 in 5 patients.
- The developing company has said that most were mild, moderate, or controllable.
- But in some cases more severe side effects have been described as including chest and back pains, muscle cramps, sweating and flushes.
- Did you ever believe that there was so much to learn about Gout Drug?
- Neither did we!
- Once we got to write this article, it seemed to be endless.